Cytokinetics (CYTK), Incorporated announced that MYQORZO has been approved by the China National Medical Products Administration, NMPA, for the treatment of adults with New York Heart Association, NYHA, class II-III obstructive hypertrophic cardiomyopathy, oHCM, to improve exercise capacity and symptoms. Under the terms of its license and collaboration agreement with Cytokinetics, Sanofi has exclusive rights to develop and commercialize MYQORZO for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy in Greater China. The approval of MYQORZO in oHCM in China triggers a $7.5 million milestone payment from Sanofi to Cytokinetics. Cytokinetics remains eligible to receive up to $142.5 million in development and commercial milestone payments from Sanofi as well as royalties in the low-to-high teens on future sales of MYQORZO in Greater China.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Receives EU Recommendation for MYQORZO®
- Cytokinetics announces positive CHMP opinion on MYQORZO
- Promising Outlook for Cytokinetics: Buy Rating Supported by Aficamten’s Advantages in HCM Treatment
- CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
- Promising Prospects for Cytokinetics’ Aficamten in oHCM and nHCM Markets